Find uplifting stories about heroes, innovations, and solutions
5 results for "rasonque"
A once-daily pill just approved by the FDA nearly doubled survival time for patients with advanced pancreatic cancer in clinical trials. The breakthrough treatment offers hope for one of the most difficult cancers to treat.
A once-daily tablet just approved by the FDA nearly doubled survival time for advanced pancreatic cancer patients in clinical trials. Rasonque targets a key protein driving tumor growth in the most common and hardest-to-treat form of this devastating disease.
A groundbreaking new pill has been approved to treat pancreatic cancer, doubling survival time compared to chemotherapy and targeting the mutations found in over 90% of cases. For decades, these mutations were considered impossible to treat.
After decades of failed attempts, a new daily pill called daraxonrasib nearly doubles survival time for pancreatic cancer patients by targeting a protein mutation once thought "undruggable." The FDA approved it six months early, offering fresh hope for one of medicine's deadliest challenges.
A newly approved pill nearly doubles survival time for patients with advanced pancreatic cancer, offering real hope for one of the deadliest cancer types. The breakthrough targets a protein that drives tumor growth in 95% of pancreatic cancer cases.